Meningococcal disease
Vaccine efficacy against NMCV-5
Caused by viral, bacterial, fungal and parasitic pathogens, meningitis epidemics in sub-Saharan Africa follow a seasonal and cyclical pattern, occurring mainly during the dry season and ending with the arrival of the rains. The majority of these epidemics are caused by Neisseria meningitidis (Nm), with up to 250,000 cases annually and a case-fatality rate of 10-15%. Historically, serogroup A was responsible for major epidemics, but its impact has been eliminated thanks to the introduction of the MenAfriVac® vaccine. However, five other Nm serogroups (B, C, Y, W, X) remain capable of causing epidemics, including outbreaks due to serogroups W and X, and more recently serogroup C in Niger and Nigeria. The Men5CV vaccine, designed to protect against the five major serogroups (A, C, Y, W, X), represents a promising solution, although its duration of protection remains unknown and data on its efficacy in real-life conditions are needed.
Objective
- To estimate the field effectiveness of NmCV-5 in reducing the risk of invasive meningococcal disease of serogroups A, C, W, Y and X in people vaccinated as part of a reactive vaccination campaign in response to an epidemic or a preventive vaccination campaign in high-risk districts.
Who’s involved besides MSF?
WHO, MSP/P/AS, CDC USA
Country
Niger
Status
Recruitment underway
Tentative End date
June 2025
Our Role
Coordination
